Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

BASEL, Switzerland and LONDON and NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced that they will host a live investor video conference at 1:00 PM ET on Tuesday, June 17 on brepocitinib, the unmet medical need for patients with dermatomyositis (DM) and the potential role brepocitinib could play in improving the lives of patients with DM.